somatrem 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
growth hormone derivatives	5042	82030-87-3

Description:

Molecule	Description
Synonyms: somatrem somatrem (genetical recombination) methionyl human growth hormone protropin somatonorm	was MH (1997-2002), demoted; an analog of the synthetic human growth hormone (human somatropin) in which a methionyl amino-acid residue is added. It may be produced in bacteria from recombinant DNA. It is used in therapy for growth hormone deficiency. Do not confuse somatrem with sometribove (methionyl bovine somatotropin). Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

somatrem
somatrem (genetical recombination)
methionyl human growth hormone
protropin
somatonorm

was MH (1997-2002), demoted; an analog of the synthetic human growth hormone (human somatropin) in which a methionyl amino-acid residue is added. It may be produced in bacteria from recombinant DNA. It is used in therapy for growth hormone deficiency. Do not confuse somatrem with sometribove (methionyl bovine somatotropin).

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Oct. 17, 1985	FDA	GENENTECH

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Clear cell renal cell carcinoma	256.33	98.88	34	186	1113	34955598
Lymphoproliferative disorder	226.50	98.88	34	186	2725	34953986

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Clear cell renal cell carcinoma	276.43	85.26	36	172	2540	79741640
Lymphoproliferative disorder	248.38	85.26	36	172	5579	79738601
Renal cell carcinoma	94.05	85.26	16	192	6562	79737618

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H01AC02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin and somatropin agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Pituitary dwarfism	indication	367460001	DOID:0060870
Growth retardation	indication	444896005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Growth hormone receptor	GPCR	P10912	GHR_HUMAN	AGONIST				SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE

External reference:

ID	Source
CU8D464EDW	UNII
D05884	KEGG_DRUG
4019548	VUID
N0000147652	NUI
4019548	VANDF
C0143083	UMLSCUI
CHEMBL1201620	ChEMBL_ID
5487805	PUBCHEM_CID
DB09098	DRUGBANK_ID
5528	INN_ID
C447442	MESH_SUPPLEMENTAL_RECORD_UI
202986	RXNORM
3666	MMSL
5500	MMSL
d00576	MMSL
002105	NDDF
109052005	SNOMEDCT_US
125578008	SNOMEDCT_US

Pharmaceutical products:

None